| 3.71 -0.08 (-2.11%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.06 | 1-year : | 5.92 |
| Resists | First : | 4.34 | Second : | 5.06 |
| Pivot price | 3.57  |
|||
| Supports | First : | 3.51 | Second : | 3 |
| MAs | MA(5) : | 3.82 |
MA(20) : | 3.54 |
| MA(100) : | 3.89 |
MA(250) : | 2.79 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 65.9 |
D(3) : | 74.1 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 5.32 | Low : | 1.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MDXH ] has closed below upper band by 37.5%. Bollinger Bands are 0.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.83 - 3.86 | 3.86 - 3.88 |
| Low: | 3.64 - 3.67 | 3.67 - 3.69 |
| Close: | 3.67 - 3.71 | 3.71 - 3.75 |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Wed, 14 Jan 2026
Analysts Expect Breakeven For MDxHealth SA (NASDAQ:MDXH) Before Long - simplywall.st
Mon, 12 Jan 2026
MDxHealth Posts Strong 2025 Revenue Growth, Sets 2026 Outlook and Revises Exact Sciences Earnout - TipRanks
Mon, 12 Jan 2026
MDXH Projects Strong Revenue Growth and Ambitious 2026 Targets - GuruFocus
Mon, 12 Jan 2026
MDxHealth reports 23% revenue growth in Q4, issues 2026 guidance - Investing.com
Thu, 08 Jan 2026
Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term - Yahoo Finance
Tue, 06 Jan 2026
World’s largest prostate cancer trial adds genomic test to guide care - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.621e+007 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.18 |
| Profit Margin | -30.5 % |
| Operating Margin | -9.7 % |
| Return on Assets (ttm) | -5.6 % |
| Return on Equity (ttm) | -720.1 % |
| Qtrly Rev. Growth | 17.7 % |
| Gross Profit (p.s.) | 179321 |
| Sales Per Share | 278102 |
| EBITDA (p.s.) | -19076.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -7.14 |
| PEG Ratio | 0 |
| Price to Book value | -21.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 39440 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|